Clinical trials: Rectum Neoplasms
Rectal Neoplasm, Neoadjuvant Therapy
Preoperative Chemoradiotherapy With Capecitabine Plus Irinotecan in Rectal Cancer
This study is to evaluate the pathologic complete response rate to pre-operative concurrent chemoradiotherapy with capecitabine plus irinotecan in resectable rectal cancer
- Trial name
- NCT00506623
- Testing
- Capecitabine, Irinotecan
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- National Cancer Center, Korea
Rectal Cancer, Rectum Neoplasm
Local Excision for Organ Preservation in Early REctal Cancer With No Adjuvant Treatment
Rectal cancer is one of the most frequent malignant tumors nowadays. There are several possible treatment options including chemotherapy, radiotherapy and surgery.
- Trial name
- LORENA (NCT05927584)
- Testing
- Transanal local excision
- Where
- Spain
- Volunteers
- 145 people
- Sponsor
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Colorectal Cancer
Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer
A prospective, observational study on clinical outcomes of surgical management of primary and metastatic colorectal cancer Prospective collection of tissues to explore potential biomarkers in blood and/or primary or secondary…
- Trial name
- ACROBATICC (NCT01762813)
- Testing
- open and laparoscopic surgery
- Where
- Norway
- Volunteers
- 1,200 people
- Sponsor
- Helse Stavanger HF
Rectal Adenocarcinoma, High-risk Locally Advanced
A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial)
This study adopts a prospective randomized controlled design to evaluate the efficacy and safety of short-course radiotherapy followed by sequential PD-1 inhibitor and FOLFOX chemotherapy versus conventional regimens in high-risk…
- Conditions
- Rectal Adenocarcinoma, High-risk Locally Advanced, Short-course Radiotherapy (SCRT), Immunotherapy
- Trial name
- STAR (NCT07669220)
- Testing
- Short-course Radiotherapy, SCRT, Toripalimab
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Rectal Cancer, Rectal Adenocarcinoma
A Trial of Durvalumab (MEDI 4736) in Combination With Extended Neoadjuvant Regimens in Rectal Cancer
PRIME-RT is an open label, multi-centre phase II randomised trial with 1:1 allocation between arm A and arm B. The principal research question is whether the addition of durvalumab to FOLFOX chemotherapy and radiation treatment…
- Conditions
- Rectal Cancer, Rectal Adenocarcinoma, Rectal Neoplasms
- Trial name
- PRIME-RT (NCT04621370)
- Testing
- Durvalumab, FOLFOX, Short Course Radiotherapy (Arm A)
- Volunteers
- 48 people
- Sponsor
- Liz-Anne Lewsley
Cancer of Rectum, Lymph Node Disease
Survival of Patients With a Reduction in the Number of Lymph Nodes in Rectal Cancer After Neoadjuvant Chemoradiotherapy
Objective: To analyze the survival of patients with a reduction in the number of resected LN in patients submitted to neoadjuvant and total excision of the mesorectum with rectal cancer.
- Trial name
- NCT04456283
- Testing
- Survival
- Where
- Brazil
- Volunteers
- 250 people
- Sponsor
- University of Sao Paulo
Anal Cancer
Image Fusion PET, CT and 3D-ultrasound Examinations
CT-examinations are used in computer programs which are used in the planning of external radiation of cancers in the anal canal. In CT the structures of the anal canal are hardly visible.
- Trial name
- NCT00302094
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Rectal Cancer
Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal Cancer
The standard treatment for stage 2/3 rectal cancer is neoadjuvant 5-Fu based chemoradiation. However, preoperative radiation cause kinds of adverse events, some were irreversible. And the survival benefit was not obvious.
- Trial name
- FORTUNE (NCT02217020)
- Testing
- FOLFOXIRI
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Solid Tumor, Colorectal Cancer
Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer
Prospective, open label, multi-dose, sequential dose escalation, single-center, Phase 1 trial
- Conditions
- Solid Tumor, Colorectal Cancer, Sigmoid Colon Cancer, Rectosigmoid Junction Cancer
- Trial name
- NCT05943041
- Testing
- GB104(Level 1), GB104(Level 2), GB104(Level 3)
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- GILongevity
Rectal Cancer Stage, Oesophageal Cancer
PD-L1 PET Imaging During Neoadjuvant (Chemo)Radiotherapy in Esophageal and Rectal Cancer
The overall aim of this pilot study is to prospectively monitor programmed death-ligand 1 (PD-L1) expression dynamics in vivo, during neoadjuvant chemoradiotherapy (CRT) or short-course preoperative radiotherapy (SCPRT) in rectal…
- Trial name
- PETNEC (NCT04564482)
- Testing
- CRT, SCPRT, CROSS Protocol
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- Johannes Laengle, MD, PhD
Colorectal Cancer, Nausea and Vomiting
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
RATIONALE: Aprepitant, palonosetron, and dexamethasone may help lessen or prevent nausea and vomiting in patients receiving chemotherapy.
- Trial name
- NCT00381862
- Testing
- aprepitant, dexamethasone, fluorouracil
- Where
- 6 sites in United States
- Volunteers
- 54 people
- Sponsor
- OHSU Knight Cancer Institute
Colorectal Cancer, Rectal Cancer
A Prediction Model of Anastomotic Stricture After Rectal Cancer
Background: Anastomotic stricture significantly impacts patients' quality of life and long-term prognosis. However, current clinical practice lacks accurate tools for predicting anastomotic stricture.
- Conditions
- Colorectal Cancer, Rectal Cancer, Anastomotic Stenosis
- Trial name
- NCT06404554
- Testing
- without any intervention
- Where
- China
- Volunteers
- 1,542 people
- Sponsor
- Northern Jiangsu People's Hospital
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose.
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06447662
- Testing
- PF-07934040, Gemcitabine, Nab-paclitaxel
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 64 people
- Sponsor
- Pfizer
Neoadjuvant Treatment, Rectal Cancer
Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Prospectively Investigate the effectiveness and safety of anlotinib hydrochloride combined with Capeox in neoadjuvant treatment of patients with locally advanced rectal cancer.
- Conditions
- Neoadjuvant Treatment, Rectal Cancer, Anlotinib
- Trial name
- NCT04620473
- Testing
- Anlotinib+Capeox, Capeox
- Sponsor
- Shanghai Minimally Invasive Surgery Center
Rectal Cancer, Radiotherapy
IMRT Versus 3DCRT for Locally Advanced Rectal Cancer, Prospective Phase II Study.
The goal of this prospective phase II study was to determine whether personalized planning-based nCRT for LARC would indeed decrease small bowel dose, and whether selected plans, specifically prioritizing lower dose to small…
- Conditions
- Rectal Cancer, Radiotherapy, Toxicity Due to Radiotherapy
- Trial name
- NCT06160570
- Testing
- Intensive Modulated Radiation Therapy, 3-Dimension Conformal Radiation Therapy
- Where
- Israel
- Volunteers
- 75 people
- Sponsor
- Rabin Medical Center
Rectal Cancer
Role of Gut Microbiota in Neoadjuvant Radioimmunotherapy for MSS, Locally Advanced Rectal Cancer
This research investigates the role of the gut microbe in patients receiving radioimmunotherapy with locally advanced microsatellite-stable (MSS) rectal cancer.
- Trial name
- NCT06898359
- Testing
- Radioimmunotherapy
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Yanhong Deng
Squamous Cell Carcinoma of the Anus Stage III
Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.
Squamous cell carcinoma of the anus (SCCA) is a rare cancer, however its incidence is increasing worldwide. SCCA is mostly induced by human papillomavirus (HPV) infections (high-risk types such as HPV-16 and -18) and HPV-related…
- Trial name
- INTERACT-ION (NCT04719988)
- Testing
- Blood sample collection, Biopsy
- Where
- 10 sites in France
- Volunteers
- 55 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Colorectal Neoplasms
Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer
The purpose of this study is to determine whether CPX-1 is effective in patients with advanced colorectal cancer who have already received chemotherapy that included the drug oxaliplatin or irinotecan.
- Trial name
- NCT00361842
- Testing
- CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
- Where
- 13 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- Jazz Pharmaceuticals
Colorectal Cancer
Amifostine Plus Irinotecan in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of amifostine plus irinotecan in treating patients with…
- Trial name
- NCT00003225
- Testing
- amifostine trihydrate, irinotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Rectal Cancer
Watchful Waiting for Complete Responders to Therapy in Rectal Cancer
The purpose of this project is to determine if in a selected group of patients, at higher risk of wound dehiscence and other complications, treatment by local excision and management by a "watchful waiting" or an initial…
- Trial name
- NCT05526079
- Testing
- Watchfuf waiting
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Henry Ford Health System
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.